Pharmaceutical Technology Editors

Cambridge Major Laboratories and AAIPharma Services plan to merge to form a global supplier of integrated CMC services.

Merck announced plans to reduce its workforce by 8,500 and move its headquarters in order to sharpen its commercial and R&D focus.

DSM Pharmaceutical Products appoints a new CEO and President.

FDA publishes guidance on ANDA submissions.

EMA revises HIV treatment guideline.

Cedarburg Hauser Pharmaceuticals has upgraded its API plant in Wisconsin.

West Pharmaceutical Services opens its second manufacturing plant in China to expand presence in Asian markets.

Perrigo appoints Keith Webber as head of regulatory review.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

ATMI has invested in sterile-connector and sterile-fill technology developed by Medical Instill Technologies.

Coldstream Laboratories partners with the National Cancer Institute for developing parental dosage forms for cancer drugs.

Sanofi?s plans strengthen its life-sciences presence at home in France and abroad in Africa.

Covance launches external laboratory-management services for clinical trials.

Almac introduces a web-based tool for clinical-trial drug-supply management and refrigerated reusable shippers for clinical supplies.

Molecular Profiles has secured a major pan-European formulation project, in which the company will be responsible for developing a topical and an oral formulation for Telormedix's psoriasis products, TMX-302.

A global collaboration between AbbVie and Galapagos is set to commercialize novel potentiator and combination therapies in cystic fibrosis.

Boehringer Ingelheim initiates a recall due to the potential for extrinsic foreign particles in the API used to manufacture Spiriva Handihaler (tiotropium bromide inhalation powder) capsules.

GE Healthcare Life Sciences announced that it will build a KUBio modular biopharmaceutical factory in China for JHL Biotech.

Capsugel?s Dosage Form Solutions business unit will expand facilities in France, the UK, and the US.

CHMP recommended 11 new medicines for approval, the most approval recommendations at a CHMP meeting thus far in 2013.

CDC says antibiotic resistance is a quickly growing and dangerous problem.

Aesica Pharmaceuticals has built a new high-capacity manufacturing facility specifically for the production of solid dose medications used in the treatment of type II diabetes at its UK site in Queenborough, Kent.

Takeda Pharmaceutical and Arbor Pharmaceuticals enter into a license, development and commercialization agreement for Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone).

The Biomanufacturing Research Program (BioMAN) at Massachusetts Institute of Technology (MIT) has received $10.4 Million from the Defense Advanced Research Projects Agency (DARPA) to develop new technologies and manufacturing platforms that will provide an emergency supply of medicines for front-line military medics.

Shamrock Medical Solutions Group, a drug repackaging and distribution company, repeatedly failed to comply with good manufacturing practices.

ScinoPharm Taiwan will provide commercial manufacturing of the API topiramate to Supernus Pharmaceuticals.

Theorem Clinical Research?s alliance with Charles River Laboratories will provide nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology.

Sanofi withdraws its new drug application (NDA) in the US for lixisenatide and plans to file a NDA in 2015.

Unilife grants Sanofi long-term exclusivity for the use of Unilife?s prefilled syringe with Sanofi?s Lovenox.

Columbia Laboratories acquires Molecular Profiles in multimillion-dollar deal.